Press release
Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047
LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that five abstracts will be presented from the KER-050 and KER-047 hematology programs at the 64th American Society of Hematology (“ASH”) Annual Meeting and Exposition, to be held in person and virtually from December 10 through 13, 2022. Keros will be presenting additional and initial preliminary results, respectively, from its two Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”) and one in patients with myelofibrosis. In addition, Keros will be presenting preliminary results from its Phase 2 clinical trial of KER-047 in patients with iron-refractory iron deficiency anemia. “We are excited to have multiple abstracts accepted for presentation at ASH, which provides us with the opportunity to share updates from our preclinical and Phase 2 clinical programs, including biomarker data from our ongoing Phase 2 clinical trial of KER-050 in patients with MDS,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “We remain on track to release additional efficacy data from our KER-050 Phase 2 MDS trial by mid-December 2022.” The following abstracts were posted to the ASH website on November 3, 2022, 9:00 a.m. Eastern time. Clinical Presentations “Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor KER-047 for Treatment of Iron-Refractory Iron Deficiency Anemia” Publication Number: 1028Session Name: 102. Iron Homeostasis and Biology: Poster IDate: Saturday, December 10, 2022Presentation Time: 5:30 p.m. – 7:30 p.m. Central time “Effects of KER-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes” Publication Number: 3656Session Name: 102. Iron Homeostasis and Biology: Poster IIIDate: Monday, December 12, 2022Presentation Time: 6:00 p.m. - 8:00 p.m. Central time “Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of KER-050 in ...